---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-24-005990"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:08:46.462342+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tonix reports Q1 net loss $14.9M; cash at $7.0M; advancing Tonmya NDA

## Summary
- Net product revenue $2.5M from Zembrace/Tosymra; net loss $(14.9)M ($0.18/share) vs $(33.0)M ($3.21) YoY.
- Cash $7.0M at Mar 31, 2024, down from $24.9M Dec 31; net cash used in ops $17.6M.
- On track to submit NDA for Tonmya in H2 2024; pre-NDA FDA meeting scheduled Q2 2024.
- Raised $4.4M in registered direct offering on Apr 1, 2024 (post-quarter).
- R&D expenses down to $12.9M from $26.5M; G&A up to $9.3M from $7.4M.

## SEC filing metadata
- accession: 0001999371-24-005990
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937124005990/0001999371-24-005990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937124005990/tnpx_8k-051324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-24-005990
- JSON: https://secwatch.observer/filing/0001999371-24-005990.json
- Plain text: https://secwatch.observer/filing/0001999371-24-005990.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000199937124005990/0001999371-24-005990-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.